Visfatin and ghrelin: can they be forthcoming biomarkers or new drug targets for asthma?

Basit Öğe Kaydı
dc.authoridCETINKAYA, ERDOGAN/0000-0002-0891-0020
dc.authoridAyada, Ceylan/0000-0002-6272-4173
dc.authoridAcat, Murat/0000-0002-7163-4882
dc.contributor.authorToru, Umran
dc.contributor.authorAyada, Ceylan
dc.contributor.authorGenc, Osman
dc.contributor.authorSahin, Server
dc.contributor.authorArik, Ozlem
dc.contributor.authorAcat, Murat
dc.contributor.authorBulut, Ismet
dc.date.accessioned2024-09-29T16:11:27Z
dc.date.available2024-09-29T16:11:27Z
dc.date.issued2015
dc.departmentKarabük Üniversitesien_US
dc.description.abstractBackground & aim: Asthma represents chronic inflammation of the airways and is associated with bronchial hyperresponsiveness and reversible airway obstruction. A novel adipokine visfatin and an appetite-modulating hormone ghrelin play a role in several diseases related with inflammation. Although visfatin is a pro-inflammatory adipokine, ghrelin mainly exerts anti-inflammatory effects. However, very little is known about the role of visfatin and ghrelin in asthma. In the present study, we aimed to investigate the role of visfatin and ghrelin in asthma by evaluating their serum levels in asthmatic patients. Materials and methods: This study was performed on 27 asthma and 23 healthy controls. Blood samples were collected in tubes without EDTA. Serum levels of visfatin and ghrelin were measured by human ELISA assay kits. Statistical analyses were performed by SPSS 16.0 package program and differences were considered statistically significant at p < 0.05. Results: Serum levels of visfatin and ghrelin were significantly higher in asthma group (respectively; p = 0.001, p = 0.002). Conclusion: While visfatin has a pro-inflammatory role, ghrelin exerts an anti-inflammatory effect in asthma. Therefore, visfatin can be a forthcoming biomarker and ghrelin may be a new anti-inflammatory drug target to diagnose and treat asthmatic patients.en_US
dc.description.sponsorshipDumlupinar University Scientific Research Fund Commission [2013/15]en_US
dc.description.sponsorshipThis study was supported by Dumlupinar University Scientific Research Fund Commission (Project No: 2013/15).en_US
dc.identifier.endpage6261en_US
dc.identifier.issn1940-5901
dc.identifier.issue4en_US
dc.identifier.pmid26131235en_US
dc.identifier.startpage6257en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14619/8442
dc.identifier.volume8en_US
dc.identifier.wosWOS:000358377700187en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherE-Century Publishing Corpen_US
dc.relation.ispartofInternational Journal of Clinical and Experimental Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAsthmaen_US
dc.subjectinflammationen_US
dc.subjectvisfatinen_US
dc.subjectadipokineen_US
dc.subjectghrelinen_US
dc.subjectappetite-modulating hormoneen_US
dc.subjectbiomarkeren_US
dc.subjectdrug targeten_US
dc.titleVisfatin and ghrelin: can they be forthcoming biomarkers or new drug targets for asthma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu